What question did this study set out to answer?

This research aims to evaluate the immunological effects of venetoclax-based therapies in chronic lymphocytic leukemia (CLL).

December 8, 2025Blood

Venetoclax-based therapy remodels T-cell and NK-cell immunity in patients with chronic lymphocytic leukemia

View Full Paper

Ask AI

Bookmark

Authors

AFAnna Maria Frustaci MVMarzia Varettoni MMMaria Chiara Montalbano

Discussion

Member takes

Overview

Observational study shows venetoclax modifies T-cell and NK-cell immunity in chronic lymphocytic leukemia, suggesting implications for immune checkpoint regulation.

Key Points

This research aims to evaluate the immunological effects of venetoclax-based therapies in chronic lymphocytic leukemia (CLL).
Multicenter observational study involving 68 patients with relapsed/refractory CLL.
Assessment of T-cell and NK-cell profiles using flow cytometry.
Monitoring changes at 1, 6, and 12 months after treatment initiation.
Venetoclax treatment significantly reduced CD3⁺, CD4⁺, and CD8⁺ T-cell counts.
Increase in terminally differentiated T cells was observed, alongside decreased effector memory T cells.
Improvement in T-cell homing capacity indicated by increased CD62L expression after 12 months.
The NK-cell subset responsible for cytotoxic activity increased significantly over time.

Cite This Study

Frustaci et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8a7 https://doi.org/10.1182/blood-2025-5657

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

Venetoclax-based therapy remodels T-cell and NK-cell immunity in patients with chronic lymphocytic leukemia

View Full Paper

Ask AI

Bookmark

Authors

AFAnna Maria Frustaci MVMarzia Varettoni MMMaria Chiara Montalbano

Discussion

Member takes

Overview

Observational study shows venetoclax modifies T-cell and NK-cell immunity in chronic lymphocytic leukemia, suggesting implications for immune checkpoint regulation.

Key Points

This research aims to evaluate the immunological effects of venetoclax-based therapies in chronic lymphocytic leukemia (CLL).
Multicenter observational study involving 68 patients with relapsed/refractory CLL.
Assessment of T-cell and NK-cell profiles using flow cytometry.
Monitoring changes at 1, 6, and 12 months after treatment initiation.
Venetoclax treatment significantly reduced CD3⁺, CD4⁺, and CD8⁺ T-cell counts.
Increase in terminally differentiated T cells was observed, alongside decreased effector memory T cells.
Improvement in T-cell homing capacity indicated by increased CD62L expression after 12 months.
The NK-cell subset responsible for cytotoxic activity increased significantly over time.

Cite This Study

Frustaci et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8a7 https://doi.org/10.1182/blood-2025-5657

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark